{Reference Type}: Journal Article
{Title}: The clinical implications of staging laparoscopy in the diagnostic workup of gastric cancer patients: A population based study.
{Author}: van der Sluis K;Vollebergh MA;Kodach LL;van Dieren JM;de Hingh IHJT;Wijnhoven BPL;Verhoeven RHA;Sandick JWV;
{Journal}: Eur J Surg Oncol
{Volume}: 50
{Issue}: 10
{Year}: 2024 Aug 2
{Factor}: 4.037
{DOI}: 10.1016/j.ejso.2024.108569
{Abstract}: <B>BACKGROUND: </B>Since 2016, staging laparoscopy has been implemented in the diagnostic workup of patients with gastric cancer. Staging laparoscopy aims to detect incurable disease (peritoneal metastases and irresectable tumors) and to prevent futile laparotomies.<BR><B>METHODS: </B>In this population-based nationwide study, we sought patient- and tumor characteristics associated with undergoing a staging laparoscopy. Additionally, we analyzed the prevalence of synchronous peritoneal metastases, the outcome of the staging laparoscopy and its clinical impact on treatment decisions. All patients diagnosed with non-cardia gastric cancer from the Netherlands Cancer Registry between 2016 and 2021 were included.<BR><B>RESULTS: </B>Alongside tumor characteristics, patient characteristics such as younger age, absence of comorbidities and lower WHO performance status were associated with performing a staging laparoscopy. In the study period, an increase in the proportion of patients who underwent a staging laparoscopy was observed, from 19.6% in 2016 to 32.3% in 2021 (p-value<0.001). In the same period, the prevalence of synchronous peritoneal metastases increased from 25% to 31%. In 37.6% of the patients who had the outcome of their staging laparoscopy reported, had incurable disease diagnosed during staging laparoscopy. Significantly less of these patients were treated with triplet regimens as compared to patients with a negative staging laparoscopy (18.5 vs. 76.3%; p-value<0.001).<BR><B>CONCLUSIONS: </B>The implementation of staging laparoscopy in gastric cancer patients paralleled the increase in diagnosis of incurable disease and a decrease in the application of triplet systemic therapies in these patients.